Halozyme Therapeutics, Inc. $HALO Stock: Illinois Municipal Retirement Fund Boosts Position

Illinois Municipal Retirement Fund boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 103,565 shares of the biopharmaceutical company’s stock after purchasing an additional 12,752 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.09% of Halozyme Therapeutics worth $11,434,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HALO. Hilton Head Capital Partners LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth $33,000. CoreCap Advisors LLC grew its stake in Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 150 shares during the last quarter. MidFirst Bank acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In other news, Director Matthew L. Posard sold 5,230 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director owned 53,609 shares of the company’s stock, valued at $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 124,226 shares of company stock worth $13,370,893 over the last ninety days. 2.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. TD Cowen lifted their target price on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $108.18.

Halozyme Therapeutics Stock Down 1.3%

HALO opened at $101.68 on Thursday. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50. The firm has a market cap of $11.59 billion, a P/E ratio of 18.49, a PEG ratio of 0.39 and a beta of 0.92. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $134.00. The business’s fifty day simple moving average is $114.95 and its 200 day simple moving average is $85.21.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The firm had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter last year, the business posted $1.72 EPS. The firm’s quarterly revenue was up 39.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.